Dr. Nuri Ince and the BIONIC team are developing neuro-biomarkers to improve neuromodulation therapies for epilepsy and movement disorders [1].
This research is critical because identifying precise neural patterns allows doctors to understand disease mechanisms more clearly. By refining how therapies are delivered, the team aims to create more targeted treatments for patients suffering from chronic neurological conditions.
Dr. Ince, a biomedical engineer and new member of the BIONIC team, focuses on the discovery of these biomarkers through advanced signal analysis [1]. The team utilizes brain-machine interface principles to extract specific patterns from neural activity [1]. This process involves analyzing complex brain signals to find the indicators that signal the onset of a disorder or the effectiveness of a treatment.
The goal of the project is to transform how neuromodulation is applied in clinical settings [1]. Current therapies often rely on broader stimulation patterns, but the BIONIC team is working to uncover the specific biomarkers that guide more precise interventions [1].
By mapping these neural markers, the team believes they can better reveal the underlying mechanisms of epilepsy and various movement disorders [1]. This approach seeks to bridge the gap between raw neural data and actionable clinical therapy, allowing for a more personalized medical response based on a patient's unique brain activity [1].
“The BIONIC team is working to uncover the specific biomarkers that guide more precise interventions.”
The shift toward biomarker-driven neuromodulation represents a move from 'one-size-fits-all' brain stimulation to precision medicine. If the BIONIC team successfully identifies reliable neuro-biomarkers, it could reduce the side effects of brain implants and increase the efficacy of treatments for millions of people with refractory epilepsy and Parkinson's-related movement disorders.
